17β-hydroxy-18-methyl-19-nor-17α-pregna-4,6,20(Z)-trien-3-one-21-carboxylic acid γ-lactone | 1166994-38-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17β-hydroxy-18-methyl-19-nor-17α-pregna-4,6,20(Z)-trien-3-one-21-carboxylic acid γ-lactone
• 英文别名: (8R,9S,10R,13S,14S,17R)-13-ethylspiro[1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,5'-furan]-2',3-dione
• CAS: 1166994-38-2
• 化学式: C₂₂H₂₆O₃
• 分子量: 338.447
• InChiKey: IECGUXKNALUNRX-TVASPAASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE
  申请人：Klar Ulrich

  公开号：US20110021472A1

  公开（公告）日：2011-01-27

  The invention relates to 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivatives with the chemical formula I, where R 4 , R 6a , R 6b , R 7 , R 15 , R 16a , R 16b , R 18 and Z have the meanings stated in claim 1 , and their solvates, hydrates, stereoisomers and salts. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action.

  本发明涉及具有化学式I的17-羟基-19-去氢-21-羧酸类固醇γ-内酯衍生物，其中R4，R6a，R6b，R7，R15，R16a，R16b，R18和Z具有权利要求1中所述的含义，以及它们的溶剂化物，水合物，立体异构体和盐。本发明进一步涉及使用这些衍生物制备口服避孕药和治疗围绝经期和绝经后症状的药物，以及包含这些衍生物的药物。本发明中的衍生物具有孕激素作用，在优选情况下还具有抗矿皮质激素和中性至轻度雄激素作用。
• US8937058B2
  申请人：——

  公开号：US8937058B2

  公开（公告）日：2015-01-20